Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
Gandhi, L Camidge, D Ribeiro de, O Bonomi, P Gandara, D Khaira, D Hann, C McKeegan, E Litvinovich, E Hemken, P
Gandhi, L
Camidge, D
Ribeiro de, O
Bonomi, P
Gandara, D
Khaira, D
Hann, C
McKeegan, E
Litvinovich, E
Hemken, P
Citations
Altmetric:
Abstract
Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors.
Description
Date
2011-03-01
Publisher
Collections
Keywords
Type
Article
Citation
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. 2011, 29 (7):909-16 J Clin Oncol